Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Valneva SE is a specialty vaccine biotechnology company focused on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company operates within the biopharmaceuticals and vaccines industry, serving primarily public health authorities, governments, and travelers in endemic and non-endemic markets. Its core revenue is derived from marketed vaccines and, to a lesser extent, from research collaborations and milestone payments.
Valneva’s differentiated positioning lies in its focus on vaccines for diseases where there are limited or no existing preventive options, combined with in-house capabilities spanning research, clinical development, manufacturing, and commercialization. The company was formed in 2013 through the merger of French company Vivalis and Austrian vaccine manufacturer Intercell, creating a cross-border European vaccine specialist with established products and late-stage development assets.
Business Operations
Valneva operates through an integrated business model encompassing vaccine discovery, development, manufacturing, and global distribution. Its commercial portfolio includes IXIARO® (Japanese encephalitis vaccine), DUKORAL® (cholera and ETEC diarrhea vaccine), and IXCHIQ® (chikungunya vaccine), which together represent the company’s primary revenue-generating products. Revenue is generated through direct sales in certain markets and through distribution partnerships in others, including government procurement and travel medicine channels.
The company maintains manufacturing and R&D operations in France, Austria, and Sweden, with clinical development activities conducted internationally. Valneva also engages in strategic collaborations with public institutions and private partners to co-develop vaccine candidates and support funding for late-stage development. Its operations are regulated by European, U.S., and other international health authorities.
Strategic Position & Investments
Valneva’s strategy centers on advancing a focused pipeline of vaccines targeting infectious diseases with high public health relevance and limited commercial competition. Growth initiatives include lifecycle management of existing products, geographic expansion of approved vaccines, and late-stage development of pipeline candidates such as its Lyme disease vaccine candidate developed in partnership with Pfizer Inc..
The company has made significant investments in manufacturing infrastructure to support both commercial supply and future product launches. Valneva’s pipeline has historically included candidates addressing Lyme disease, chikungunya, and other viral or bacterial infections, reflecting its emphasis on niche but globally relevant indications. Where applicable, development risk is shared through partnerships, non-dilutive funding, or advance purchase agreements with government entities.
Geographic Footprint
Valneva is headquartered in Saint-Herblain, France, and operates across Europe, North America, and select markets in Asia-Pacific. Its operational footprint includes manufacturing sites in France and Austria, as well as research activities in Sweden, providing the company with a strong European industrial base.
Commercially, Valneva’s vaccines are sold in more than 40 countries, with particularly strong presence in Europe, the United States, and international travel medicine markets. The company also has exposure to emerging markets through public-sector tenders and global health initiatives, extending its international reach beyond traditional commercial pharmaceutical markets.
Leadership & Governance
Valneva is led by an experienced executive team with backgrounds in vaccines, pharmaceuticals, and life sciences commercialization. The leadership emphasizes disciplined capital allocation, partnership-driven development, and a targeted approach to vaccine innovation focused on unmet needs rather than mass-market immunizations.
Key executives include:
- Thomas Lingelbach – Chief Executive Officer
- Franck Grimaud – Chief Financial Officer
- François Dubovsky – Chief Medical Officer
- Juan Carlos Jaramillo – Chief Commercial Officer
- Michael Kress – Chief Operating Officer